2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
2 citations
,
July 2024 in “Pilot and Feasibility Studies” The online low-carb program was feasible and acceptable for young women with obesity.
2 citations
,
January 2022 in “Journal of the American Academy of Dermatology” Virtual reality can reduce pain during scalp injections.
2 citations
,
September 2021 Patients with alopecia areata may have lower vitamin D levels than healthy people.
2 citations
,
February 2021 in “International Journal of Environmental Research and Public Health” Women with PCOS tend to be less optimistic than those without it.
Women with Polycystic Ovary Syndrome (PCOS) have a lower health-related quality of life, especially those with an anovulatory phenotype, and need specific interventions to improve it.
1 citations
,
September 2017 C-scores can help predict gain-of-function and loss-of-function mutations.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” UV photography can help identify people at higher risk for skin cancer, and male pattern baldness at age 45 is linked to a higher risk of certain skin cancers.
January 2026 in “Journal of Ayurveda Case Reports” Ayurvedic treatment led to complete hair regrowth in a patient with Alopecia Areata.
January 2026 in “Al-Azhar Assiut Medical Journal” Intralesional pentoxifylline effectively and safely treats alopecia areata, improving hair regrowth.
Virtual healthcare significantly improves quality of life for men with hair loss if they stick to the treatment.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
Combining bromelain with finasteride improves hair regrowth and reduces inflammation in alopecia.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
January 2019 in “Egyptian Journal of Dermatology and Venereology /Egyptian Journal of Dermatology and Venerology” Low vitamin D levels might indicate more severe hair loss in alopecia areata patients.
January 2019 in “Egyptian Journal of Dermatology and Venereology /Egyptian Journal of Dermatology and Venerology” Mixing calcipotriol with a steroid is almost as effective as using a steroid alone for alopecia areata and has fewer side effects.
February 2023 in “Cureus” Male pattern baldness in medical students is linked to higher depression, loneliness, and internet addiction.
38 citations
,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
4 citations
,
December 2010 in “Journal of the American Geriatrics Society” Thalamic stroke can cause delirium without other symptoms, especially in older adults.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.